From phase III immunotherapy and antibody-drug conjugate trials to the possibility of eliminating breast surgery, the SABCS 2026 is preparing to address some of the most consequential unanswered questions in modern breast oncology. Based on the newly released presentation titles, OncoDaily Breast has selected 10 studies with particularly strong potential to influence clinical practice, treatment sequencing, and precision oncology.
The San Antonio Breast Cancer Symposium (SABCS) will take place December 8–11, 2026, bringing together clinicians, researchers, and patient advocates to discuss advances spanning early-stage and metastatic breast cancer.
The scientific program includes major randomized trials, biomarker-validation studies, surgical and radiotherapy de-escalation research, and novel therapeutic strategies across triple-negative, HER2-positive, and hormone receptor-positive disease. The 2026 meeting comes at a particularly important moment in breast oncology.
Antibody-drug conjugates are increasingly moving into earlier treatment lines. Immunotherapy has become a component of curative-intent treatment for high-risk triple-negative breast cancer (TNBC). HER2-directed treatment is evolving beyond conventional chemotherapy-containing strategies, while artificial intelligence and molecular response assessment are being investigated to improve treatment selection.
At the same time, trials are challenging long-established local treatment principles by investigating whether surgery, axillary treatment, or radiotherapy can be omitted in carefully selected patients.
The following selection prioritizes the clinical importance of the research question, trial maturity, potential to change current treatment standards, and implications for future studies.
Editorial note: As of November 2, 2026, SABCS has released presentation titles but not full abstract text. Accordingly, this is a preconference evidence-based preview. It does not assume positive or negative results, and newly presented efficacy or safety outcomes will require assessment once the embargoes lift.
1. SWOG S1418/NRG BR006: Can Adjuvant Pembrolizumab Improve Outcomes in TNBC With Residual Disease?
Presentation: GS1-4 | General Session 1 | December 9
Presenter: Lajos Pusztai, MD, Yale School of Medicine
One of the most consequential presentations at SABCS 2026 will be the efficacy results of the randomized phase III SWOG S1418/NRG Oncology BR006 trial.
The study evaluates adjuvant pembrolizumab in patients with triple-negative breast cancer who have residual invasive disease after neoadjuvant chemotherapy. Residual disease after neoadjuvant treatment represents a clinically important population because failure to achieve pathological complete response is associated with a higher risk of recurrence.
The introduction of perioperative pembrolizumab through KEYNOTE-522 has substantially improved outcomes in high-risk early-stage TNBC. However, an important distinction remains: KEYNOTE-522 initiated immunotherapy before surgery and continued it afterward.
SWOG S1418 addresses a different question—whether introducing pembrolizumab after surgery provides benefit to patients who have already completed neoadjuvant chemotherapy but retain residual invasive disease.
This distinction makes the study particularly relevant for patients who did not receive preoperative immunotherapy and subsequently require postoperative risk-adapted treatment. The most important findings to examine will be invasive disease-free survival, distant recurrence, overall survival, and immune-related toxicity.
A favorable result could establish evidence for an adjuvant-only immunotherapy strategy in a clearly defined high-risk population. Conversely, a negative result would reinforce the importance of initiating immune checkpoint blockade earlier in the treatment course. Either outcome could have meaningful implications for postoperative TNBC management.
2. OptiTROP-Breast03: Can Sacituzumab Tirumotecan Redefine First-Line Treatment for Metastatic TNBC?
Presentation: GS1-8 | General Session 1 | December 9
Presenter: Lei Fan, Fudan University Shanghai Cancer Center
Antibody-drug conjugates have rapidly transformed metastatic TNBC treatment, with TROP2-directed therapies increasingly moving into the first-line setting.
The randomized phase III OptiTROP-Breast03 trial evaluates sacituzumab tirumotecan against chemotherapy in patients with unresectable recurrent or metastatic TNBC who have PD-L1 combined positive scores below 10 or prior early-stage exposure to PD-(L)1 inhibitors.
This population is clinically important because first-line treatment choices depend substantially on immunotherapy eligibility and previous exposure.
The successful integration of pembrolizumab-based treatment in early TNBC has created an increasingly common challenge: how should metastatic recurrence be managed after patients have already received immune checkpoint inhibitors?
Sacituzumab tirumotecan is a TROP2-directed ADC that has demonstrated significant antitumor activity in previously treated TNBC, including an overall survival benefit in the phase III OptiTROP-Breast01 trial.
OptiTROP-Breast03 therefore extends an established therapeutic concept into an earlier treatment setting. The critical questions will concern the magnitude of progression-free survival improvement, overall survival maturity, response durability, and the toxicity trade-off compared with standard chemotherapy.
It will also be important to examine outcomes according to prior immunotherapy exposure and PD-L1-defined subgroups. If positive, the results could further accelerate the transition from conventional chemotherapy toward ADC-based first-line treatment for metastatic TNBC.
3. AMATERAS-BC: Could Breast Surgery Be Safely Omitted in Selected HER2-Positive Patients?
Presentation: GS2-1 | General Session 2 | December 10
Presenter: Tomomi Fujisawa, Gunma Prefectural Cancer Center
Perhaps the most provocative question at SABCS 2026 concerns whether surgery is always necessary after an excellent response to HER2-targeted systemic treatment.
The prospective phase III AMATERAS-BC study (JCOG1806) is investigating a nonsurgical treatment strategy for patients with HER2-positive primary breast cancer who achieve a clinical complete response after anti-HER2-based therapy.
The study challenges the long-standing principle that definitive breast surgery remains necessary following neoadjuvant treatment, even when imaging and clinical assessment suggest complete tumor regression.
Improvements in HER2-targeted systemic therapy have produced increasingly high rates of pathological complete response, creating interest in reducing local treatment intensity for exceptional responders. However, clinical complete response is not synonymous with pathological complete response.
Imaging and clinical examination may fail to identify residual microscopic invasive or in situ disease, raising concerns about local recurrence when surgery is omitted.
AMATERAS-BC is therefore particularly important because it addresses the oncological safety of a strategy that could substantially change treatment pathways, patient quality of life, and the role of local therapy.
Long-term recurrence outcomes, the reliability of response assessment, and the characteristics of patients eligible for omission will be central to interpreting its findings. Importantly, surgery omission remains investigational and should not be considered routine care before sufficient prospective evidence establishes its safety.
4. WSG ADAPT-HER2-IV: Can Neoadjuvant T-DXd Monotherapy Replace More Intensive Treatment?
Presentation: GS3-5 | General Session 3 | December 11
Presenter: Nadia Harbeck, MD, PhD
The first results of WSG ADAPT-HER2-IV represent another highly anticipated development in early HER2-positive breast cancer. The study evaluates neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy against standard-of-care treatment in patients with stage I–II HER2-positive early breast cancer.
T-DXd has demonstrated major efficacy across HER2-positive metastatic disease and has subsequently moved into curative-intent treatment strategies. However, whether T-DXd alone can replace conventional multidrug neoadjuvant approaches in selected patients remains an important unresolved question.
The distinction between efficacy in advanced disease and curative-intent treatment is critical. In early-stage disease, the objective is not simply tumor shrinkage but durable eradication of micrometastatic disease while minimizing long-term toxicity.
The findings from ADAPT-HER2-IV may therefore provide important evidence regarding pathological complete response, treatment feasibility, and the potential role of an ADC-based chemotherapy-sparing strategy.
Safety will be equally important, particularly interstitial lung disease/pneumonitis and treatment discontinuation. Results should also be interpreted according to disease stage, hormonal receptor status, and the treatment regimens used in the comparator group.
The study is especially relevant alongside DESTINY-Breast11, which investigated a sequential T-DXd-containing strategy rather than T-DXd monotherapy as a complete substitute for standard neoadjuvant treatment.
ADAPT-HER2-IV could help clarify how far HER2-directed ADC-based treatment de-escalation can safely progress.
5. ASCENT-07: Will Updated Overall Survival Change the Interpretation of Sacituzumab Govitecan in HR-Positive Disease?
Presentation: RF2-1 | Rapid Fire 2 | December 8
Presenter: Hope S. Rugo, MD, City of Hope Comprehensive Cancer Center
The updated overall survival analysis from the phase III ASCENT-07 trial deserves close attention because it may change the interpretation of previously reported results.
ASCENT-07 evaluates sacituzumab govitecan against physician’s choice chemotherapy as the first chemotherapy treatment following endocrine therapy in patients with HR-positive/HER2-negative unresectable locally advanced or metastatic breast cancer.
The original primary analysis did not meet the prespecified progression-free survival endpoint by blinded independent central review. However, early overall survival findings showed a favorable numerical trend, creating interest in whether additional follow-up might clarify a survival advantage.
The updated analysis will therefore be important for determining whether the treatment demonstrates clinically meaningful benefits despite the negative primary PFS result. Any apparent OS advantage must be interpreted in the context of the statistical testing plan, maturity of survival data, subsequent treatments, and the original endpoint hierarchy.
The study is particularly relevant because HR-positive/HER2-negative metastatic breast cancer is becoming an increasingly competitive ADC treatment landscape. Therapeutic choices now include HER2-directed ADCs for eligible HER2-low or ultralow populations and TROP2-directed ADCs across different treatment lines.
The central question is whether earlier sacituzumab govitecan use offers sufficient clinical benefit to change sequencing strategies after endocrine resistance.
6. BCTOP-T-N01: Can Antiangiogenic Targeting Improve Neoadjuvant Chemoimmunotherapy in TNBC?
Presentation: GS1-5 | General Session 1 | December 9
Presenter: Junjie Li, Fudan University Shanghai Cancer Center
The randomized phase III BCTOP-T-N01 trial investigates an intensified neoadjuvant approach for triple-negative breast cancer incorporating famitinib, camrelizumab, and chemotherapy. Camrelizumab is a PD-1 inhibitor, while famitinib is a multitarget tyrosine kinase inhibitor with antiangiogenic activity.
Combining immune checkpoint blockade with antiangiogenic treatment is biologically attractive because VEGF-dependent signaling can contribute to an immunosuppressive tumor microenvironment. The strategy aims to improve antitumor immune activity through simultaneous modification of immune signaling and tumor vasculature.
However, adding targeted therapy to chemoimmunotherapy may also increase treatment complexity and toxicity. The phase III results will need to demonstrate whether any improvement in pathological complete response or other disease outcomes justifies the additional treatment burden.
Event-free survival, surgical feasibility, dose modifications, hypertension, bleeding risk, and immune-related adverse events will be particularly important. A positive result could support further investigation of immune and angiogenic pathway co-targeting in early TNBC.
Nevertheless, applicability outside the studied population and regulatory setting would require additional evaluation.
7. POSNOC: Can Axillary Treatment Be Omitted With Limited Sentinel Node Macrometastases?
Presentation: GS2-5 | General Session 2 | December 10
Presenter: Amit Goyal, Royal Derby Hospital
The POSNOC trial represents one of the most important surgical and radiation oncology studies scheduled for SABCS 2026. The study examines omission of axillary treatment in patients undergoing breast-conserving surgery or mastectomy who have one or two sentinel lymph nodes containing macrometastases.
Management of the axilla has evolved considerably over the past two decades, with increasing recognition that extensive axillary surgery may be unnecessary in selected patients. However, uncertainties persist regarding which patients can safely omit additional axillary surgery or nodal radiotherapy, particularly outside the populations represented in earlier de-escalation trials.
POSNOC directly addresses this clinical question. The findings may influence how multidisciplinary teams balance regional disease control against treatment-related morbidity, including lymphedema, shoulder dysfunction, pain, and restricted mobility.
The most consequential outcomes will include axillary recurrence, broader disease-free outcomes, and treatment-related complications. Patient selection and radiotherapy details will be essential to interpreting the results.
If oncological outcomes remain favorable without additional axillary treatment, POSNOC could contribute to further reductions in treatment-related morbidity for appropriately selected patients.
8. PROSPECT: Can Postoperative Radiotherapy Be Omitted in Selected Early Breast Cancer?
Presentation: GS2-3 | General Session 2 | December 10
Presenter: Bruce Mann, Royal Melbourne Hospital
The final results of the PROSPECT trial (ANZ 1002) are another important component of the 2026 de-escalation agenda. The study investigates omission of postoperative radiotherapy in selected patients with early breast cancer.
Radiotherapy following breast-conserving surgery significantly reduces ipsilateral breast tumor recurrence, but its absolute benefit varies according to patient age, tumor biology, endocrine therapy use, and baseline recurrence risk.
Several prior studies have demonstrated that radiotherapy omission may be reasonable in carefully defined lower-risk populations. The remaining challenge is improving selection beyond conventional clinicopathological characteristics.
PROSPECT may contribute evidence about whether selected patients can avoid radiotherapy without an unacceptable increase in local recurrence.
The long-term nature of recurrence risk in hormone receptor-positive breast cancer makes the duration of follow-up particularly important. Results must be evaluated in terms of local and regional recurrence, distant disease outcomes, eligibility criteria, and the consequences of omitting radiotherapy.
A favorable result would not imply that radiotherapy can be broadly omitted in all early breast cancer patients. Instead, it could help refine a more personalized approach to local treatment.
9. NeoTRACT: Can Tumor-Infiltrating Lymphocytes Guide Less Intensive TNBC Treatment?
Presentation: GS1-6 | General Session 1 | December 9
Presenter: Priyanka Sharma, MD, University of Kansas Medical Center
The phase II NeoTRACT trial examines a biologically guided approach to neoadjuvant chemoimmunotherapy in triple-negative breast cancer. Rather than applying identical treatment intensity to all patients, the study evaluates strategies informed by tumor-infiltrating lymphocytes (TILs) and treatment response.
TILs have emerged as important prognostic biomarkers in TNBC, reflecting the degree of pre-existing immune engagement within the tumor microenvironment. Patients with highly immune-infiltrated tumors may demonstrate greater sensitivity to immune-based treatment, raising the possibility of reducing chemotherapy exposure in appropriately selected cases.
However, a prognostic association with favorable outcomes does not necessarily establish a biomarker’s ability to predict the safety of treatment reduction. NeoTRACT is therefore relevant because it connects immune biology with response-adapted treatment.
The main questions concern pathological complete response, treatment completion, safety, and the consistency of outcomes across TIL-defined patient populations. The study may also provide insight into whether serial response assessment can improve individual treatment decisions.
As a phase II trial, positive findings would require further validation before establishing a new de-escalated standard. Nevertheless, NeoTRACT represents a promising step toward avoiding unnecessary treatment exposure while preserving clinical outcomes.
10. TAILORx: Can Causal Multimodal AI Improve Predictions of Chemotherapy Benefit?
Presentation: GS1-1 | General Session 1 | December 9
Presenter: Nancy Chan, NYU Langone Health
The growing role of artificial intelligence in clinical oncology will be highlighted by an external validation study of a causal multimodal AI model in patients with node-negative HR-positive/HER2-negative breast cancer from TAILORx.
The study examines whether AI integrating multiple forms of clinical and biological information can improve prognostic assessment and predictions of chemotherapy benefit. TAILORx helped establish the role of genomic recurrence scores in guiding chemotherapy decisions in node-negative HR-positive/HER2-negative early breast cancer.
However, important questions remain regarding the individual prediction of benefit, particularly when clinical factors, genomic risk, patient age, and menopausal status provide overlapping or sometimes divergent information.
A multimodal approach could potentially improve individual treatment estimation by incorporating information that is not fully captured by a single genomic score.
The key issue will be whether the model demonstrates reliable external validation, calibration, and reproducible estimates of treatment benefit. Distinguishing prediction of recurrence risk from prediction of incremental chemotherapy benefit is essential.
An AI model that identifies patients with a high probability of recurrence is not necessarily capable of identifying patients whose outcomes will improve substantially with chemotherapy. The related blinded validation study in SWOG-8814 may provide additional information about performance in node-positive hormone receptor-positive disease.
If successfully validated, these approaches could eventually support more individualized decisions. However, they would require prospective clinical utility evidence before replacing established treatment-selection tools.
Beyond the Top 10: Additional Studies Worth Following
The broader SABCS 2026 program includes several studies that could also influence future care.
The ARIADNE trial will present its first analysis of a randomized, biology-driven neoadjuvant T-DXd strategy in HER2-positive breast cancer, complementing the ADAPT-HER2-IV findings.
The SOLTI-UNICANCER RIBOLARIS study will provide updated results on chemotherapy omission guided by genomic response after neoadjuvant ribociclib and endocrine therapy in high-risk HR-positive/HER2-negative early disease.
An updated analysis from NATALEE will investigate whether IHC-based protein biomarkers provide prognostic or predictive information for adjuvant ribociclib. The Alliance ALTERNATE trial will present five-year recurrence-free survival findings evaluating a modified preoperative endocrine prognostic index after neoadjuvant anastrozole.
Other notable research includes long-term survival and homologous recombination deficiency biomarker analyses from the phase III PEARLY trial, studies evaluating quantitative HER2 assessment for T-DXd outcomes, and translational research addressing resistance to endocrine therapy and targeted treatment.
Together, these studies illustrate the increasingly important role of biomarkers in selecting not only the appropriate therapy but also the appropriate treatment intensity.
What Could Change After SABCS 2026?
Three major clinical themes emerge from the newly announced program.
The first is moving novel systemic therapies earlier in the treatment pathway. SWOG S1418, OptiTROP-Breast03, BCTOP-T-N01, and ADAPT-HER2-IV address whether immune-based or ADC-based strategies can improve outcomes in populations where established treatment still leaves important unmet needs.
The second is reducing unnecessary local and systemic treatment. AMATERAS-BC, POSNOC, PROSPECT, and NeoTRACT investigate whether carefully selected patients can achieve favorable outcomes with less intensive treatment.
The third is improving the biological precision of treatment decisions. TAILORx AI validation, genomic-response studies, and tumor immune profiling aim to move beyond conventional risk categories toward more individualized therapeutic strategies.
However, the significance of these studies will depend on more than whether a primary endpoint is met. Absolute benefit, confidence intervals, duration of follow-up, late recurrence, toxicity, patient-reported outcomes, and generalizability will determine their eventual clinical importance.
In de-escalation studies, a favorable early response or low short-term recurrence rate will not automatically establish long-term safety. Similarly, encouraging early efficacy with a novel drug must be balanced against treatment-related adverse events and the availability of established alternatives.
OncoDaily Takeaway
SABCS 2026 could become an important meeting for both treatment escalation and de-escalation in breast oncology.
The phase III SWOG S1418 and OptiTROP-Breast03 trials may influence immunotherapy and ADC-based treatment strategies in TNBC, while WSG ADAPT-HER2-IV could inform the future role of T-DXd in early HER2-positive disease.
AMATERAS-BC, POSNOC, and PROSPECT address questions that could redefine the extent of surgery and radiotherapy required for selected patients.
At the same time, NeoTRACT and the multimodal AI validation studies underscore the growing importance of biological markers for choosing not only what treatment to administer, but also how much treatment individual patients need.
The final clinical importance of each presentation remains unknown until full efficacy and safety findings become available.
The central question heading into San Antonio is whether the next generation of breast cancer care can deliver better long-term outcomes while simultaneously reducing treatment burden for patients who do not require intensive therapy.
For clinicians, the most consequential presentations may be those that establish precisely where treatment can be intensified for meaningful benefit—and where it can be safely reduced without compromising cure.
Sources
- San Antonio Breast Cancer Symposium. Abstracts and Key Dates. https://sabcs.org/abstracts/
